Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 1Patient Preference 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 3Trastuzumab 2Irinotecan 2Drug Therapy 2Cisplatin 2Capecitabine 2tivozanib 1tipifarnib 1spartalizumab 1seribantumab 1pertuzumab 1entinostat 1atezolizumab 1Thalidomide 1Ritonavir 1Quality of Life 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Paclitaxel 1Observation 1Molecular Diagnostic Techniques 1Mesna 1Magnetic Resonance Spectroscopy 1Itraconazole 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Injections, Subcutaneous 1Immunotherapy 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Injections, Subcutaneous × Breast × Clear all
NCT07036185 2025-06-25

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡